Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Merck
Argus Health
UBS
Medtronic
McKinsey

Generated: June 17, 2019

DrugPatentWatch Database Preview

Details for Patent: 10,195,214

« Back to Dashboard

Which drugs does patent 10,195,214 protect, and when does it expire?

Patent 10,195,214 protects KORLYM and is included in one NDA.

This patent has one patent family member in one country.

Summary for Patent: 10,195,214
Title:Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors
Abstract: Applicant provides methods of treating diseases including Cushing's syndrome and hormone-sensitive cancers by concomitant administration of a glucocorticoid receptor antagonist (GRA) and steroidogenesis inhibitors, and by concomitant administration of a GRA and CYP3A inhibitors. Applicant provides methods of treating diseases including Cushing's syndrome and hormone-sensitive cancers by concomitant administration of mifepristone and ketoconazole. Subjects treated with CYP3A inhibitors or steroidogenesis inhibitors may suffer from toxicity or other serious adverse reactions; concomitant administration of other drugs would be expected to increase the risk of such toxicity and adverse reactions. Applicant has surprisingly found that GRAs may be administered to subjects receiving CYP3A inhibitors or steroidogenesis inhibitors such as ketoconazole without increasing risk adverse reactions; for example, Applicant has found that mifepristone may be concomitantly administered with ketoconazole (a CYP3A inhibitor and a steroidogenesis inhibitor), providing safe concomitant administration of the GRA and ketoconazole. In embodiments, the GRA dose may be reduced.
Inventor(s): Belanoff; Joseph K. (Menlo Park, CA)
Assignee: Corcept Therapeutics, Inc. (Menlo Park, CA)
Application Number:15/627,359
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,195,214
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 10,195,214
Patent Claim Types:
see list of patent claims

Drugs Protected by US Patent 10,195,214

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Corcept Therap KORLYM mifepristone TABLET;ORAL 202107-001 Feb 17, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATING CUSHING'S SYNDROME ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
McKesson
Chinese Patent Office
Julphar
Express Scripts
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.